These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30407259)

  • 1. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?
    Nemakayala DR; Cash BD
    Curr Opin Gastroenterol; 2019 Jan; 35(1):58-62. PubMed ID: 30407259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
    Menees SB; Powell C; Kurlander J; Goel A; Chey WD
    Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
    Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
    Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
    Schoepfer AM; Trummler M; Seeholzer P; Seibold-Schmid B; Seibold F
    Inflamm Bowel Dis; 2008 Jan; 14(1):32-9. PubMed ID: 17924558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
    Li XG; Lu YM; Gu F; Yang XL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
    Dai C; Jiang M; Sun MJ
    Am J Gastroenterol; 2015 Aug; 110(8):1242-3. PubMed ID: 26263364
    [No Abstract]   [Full Text] [Related]  

  • 9. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis.
    Zhou XL; Xu W; Tang XX; Luo LS; Tu JF; Zhang CJ; Xu X; Wu QD; Pan WS
    BMC Gastroenterol; 2014 Jul; 14():121. PubMed ID: 25002150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.
    David LE; Surdea-Blaga T; Dumitrascu DL
    Sao Paulo Med J; 2015; 133(4):343-9. PubMed ID: 26039537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.
    Bosch S; van Gaal N; Zuurbier RP; Covington JA; Wicaksono AN; Biezeveld MH; Benninga MA; Mulder CJ; de Boer NKH; de Meij TGJ
    Inflamm Bowel Dis; 2018 Oct; 24(11):2468-2475. PubMed ID: 29788410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.
    Däbritz J; Musci J; Foell D
    World J Gastroenterol; 2014 Jan; 20(2):363-75. PubMed ID: 24574706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal markers: calprotectin and lactoferrin.
    Abraham BP; Kane S
    Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).
    Carrasco-Labra A; Lytvyn L; Falck-Ytter Y; Surawicz CM; Chey WD
    Gastroenterology; 2019 Sep; 157(3):859-880. PubMed ID: 31351880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.
    Gacesa R; Vich Vila A; Collij V; Mujagic Z; Kurilshikov A; Voskuil MD; Festen EAM; Wijmenga C; Jonkers DMAE; Dijkstra G; Fu J; Zhernakova A; Imhann F; Weersma RK
    Gut Microbes; 2021; 13(1):1943288. PubMed ID: 34313538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
    Caviglia GP; Pantaleoni S; Touscoz GA; Adriani A; Rosso C; Smedile A; Pellicano R; Astegiano M; Bresso F
    Scand J Gastroenterol; 2014 Dec; 49(12):1419-24. PubMed ID: 25369978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
    J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome.
    Chowdhury MFK; Ghosh CK; Miah MSA; Uddin MA; Rassell M; Rashid MH; Pal AK; Mahabub-Uz-Zaman K; Saha KP; Miah MAR
    Mymensingh Med J; 2024 Oct; 33(4):1149-1156. PubMed ID: 39351737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.